Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30–40% of treated patients have …

Objectives In locally-advanced cervical cancer (LACC), platinum-based chemoradiotherapy
(CRT) has been the standard-of-care treatment for> 20 years. CALLA is the first global …

Background Concurrent chemoradiotherapy is the standard of care for locally advanced
cervical cancer. Concurrent chemoradiotherapy with programmed blockade of the cell death …

Background Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic
cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy. In …

TPS6096 Background: High-risk locally advanced cervical cancer has a poor prognosis, and
more than half of patients recur in 2 y. External beam radiotherapy (EBRT) with concurrent …

Background There is a lack of data exploring the use and optimal timing of immunotherapy
and chemoradiation therapy (CRT) in node-positive cervical cancer. Further translational …

Concurrent chemoradiotherapy (CRT) with blockade of the PD-1 pathway may enhance
immune-mediated tumor control through increased phagocytosis, cell death, and antigen …

Background Immune checkpoint inhibitors are being considered for locally advanced
cervical cancer (LACC) together with standard‐of‐care pelvic chemoradiation (CRT) …

Background Pembrolizumab (pembro) has shown efficacy in patients (pts) with cervical
cancer. The effect of chemoradiotherapy may be enhanced by immunotherapy. ENGOT …

PURPOSE KEYNOTE-158 (ClinicalTrials. gov identifier: NCT02628067) is a phase II basket
study investigating the antitumor activity and safety of pembrolizumab in multiple cancer …